Keyword: Sanaria

The Radboud University Medical Center in the Netherlands, the Instituto de Medicina Molecular Lisboa in Portugal, and PATH are collaborating on a human trial of a novel malaria vaccine.

WHO plans real-world pilot studies of GlaxoSmithKline’s malaria jab Mosquirix in three African countries.

NIH has launched a phase 1 trial to test a vaccine that aims to fight a wide range of mosquito-borne diseases.

Sanaria’s malaria vaccine posted more positive clinical data, but a notable gap compared with results from U.S. studies calls for regimen improvements.

Sanaria's malaria vaccine is one step closer to challenging GlaxoSmithKline's Mosquirix, thanks to data from a recent clinical trial.